Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

NCT05745532 is registered in ClinicalTrials.gov with Shenzhen Hemogen as lead sponsor.

NCT NCT05745532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05745532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
Lead sponsor
Shenzhen Hemogen
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2020
Completion date
December 30, 2025
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

β-thalassemia